abstract KEYWORD INDEX EAE 2129 early arthritis 787, 1774, 2183 early arthritis clinic 661 early axial spondyloarthritis 669 E early diagnosis 550, 585 early disease 2183 early inflammatory arthritis (EIA) 659, 978, 1737 early inflammatory polyarthritis 796, 1110 early life microbial exposure 248 early osteoarthritis 184 early psoriatic arthritis 1962 early RA 1541, 1548 early response 380 early rheumatoid arthritis 300, 337, 396, 1104, 1837 echocardiography 1004 economics 51, 55, 296, 322, 754, 755, 761, 764, 767, 769, 770, 781, 791, 795, 969, 1539, 1548, 2091, 2139, 2246 education, medical 41, 42, 43, 44, 45, 46, 47, 48, 50, 162, 984, 1429, 1431, 1432, 1433, 1617, 1735 education, patient 40, 42, 108, 156, 211, 996, 1001, 1221, 1335, 1336, 2080, 2082, 2268, 2279, 2284 educational advertising 2081 effectiveness 1802 efficacy 163, 937, 1454, 1456, 1832, 2173 effusion 1754 e-health 1334 elderly people 1546 electronic health record 1005 electronic medical record 221, 998 electronic monitored system 1047, 1865 electronic reports 2248 electrostimulation 647 ELISA 1377 employment 796, 2069, 2138 employment impact 2079 employment status 1217 en bloc biopsy 921 end row capillary loops 1686 end stage renal disease 2018 endoplasmic reticulum 1376 endoscopy 298 endothelial cells 834, 1183, 1190, 1214, 1352, 1356, 1416, 1418, 1419, 1420, 1504, 1988, 1997, 2000, 2003, 2021 endothelial dysfunction 519 endothelial function 628 endothelial progenitor cells 456 endothelial protein C receptor 1190 endothelin 1294, 2003 endothelin receptor A antagonist 574 endothelin receptor antagonists 1214 endothelin-1 2231 enkephalins 1226 enolase 1717 entecavir 387 enteric coated mycophenolic adid (EC-MPS) 1402 entheses 1962 enthesitis 233, 512, 1619, 1633 environmental factors 61, 248, 510, 533, 686, 1070, 1252, 1678, 1936, 1956, 2118 enzyme-linked immunoabsorbant assays (ELISA) 1844 eosinophilic fasciitis 1624 ephrins 1991 epicardial adipose tissue 2166 epidemiologic studies 645 epidemiology 58, 100, 248, 535, 571, 649, 963, 1307, 1327, 1329, 1331, 1366, 1544, 1913, 2067, 2093, 2094 epigenetics 507, 750, 858, 1253, 1352, 1422, 1518, 1528, 1585, 1586, 1988, 2004, 2191 epistatic interactions 1596 epithelial to mesenchymal transition (EMT) 602 epitope mapping 2001 epratuzumab 453, 751, 752, 1452 Epstein Barr virus 1082, 1708 EQ-5D 2207 EQ-5D/SF-6D 787 eQTL 1608 ERAP 1969 ERAP1 1972 Erdheim-Chester disease 1660 erectile dysfunction 1544 ergocalciferol 310 ERK 32 ERK/MAPK expression 1523 erosion 889, 1370, 1621, 2256 erosive arthritis 728 erosive osteoarthritis 187, 1620 erythrocyte sedimentation rate (ESR) 919, 1304 ESCAPE RA 1018 esomeprazole 597, 937 ESRD 2022 estrogen 462 estrogen receptor 462 etanercept 69, 216, 219, 227, 229, 230, 290, 398, 514, 669, 1103, 1105, 1117, 1368, 1631, 1825, 1927, 1937, 1944, 1946, 1960 ethnic studies 571, 1464, 1674, 1877, 2082 ethnicity 446 EULAR response 1829 evidence based medicine 1560 exercise 93, 200, 628, 646, 688, 689, 691, 692, 784, 797, 1384, 1465, 1558, 1681, 2057, 2071, 2135, 2268, 2283 exercise program 2059 exercises 1458 exome 2144 experimental arthritis 278, 1532 expert opinion 1291 expression 1593 extraarticular manifestations 528, 904, 1447, 1933, 1952, 2117 extracellular DNA 1420 extracellular matrix 1722 extracellular matrix proteins 673, 887, 1294, 1421, 1719 extracellular RNA 1420 extractable nuclear antigen 1847 extra-glandular manifestations 1898 eye disease 1298 F facet joint injection 172 factor analysis 181 falls 1576 familial Mediterranean fever 666, 905, 909, 1516, 1696, 1706 family functioning 625 family physicians 1571 family studies 1068, 1145, 1193, 1851, 2083, 2144 famotidine 945, 946 Fas 853 fasciitis 921 fat mass 173, 1383 fat mass index 1018 fatigue 97, 99, 105, 113, 627, 628, 799, 800, 804, 815, 817, 819, 820, 1032, 1211, 1219, 1228, 1325, 1344, 1736, 1758, 1848, 1882, 2065 fatigue severity scale 1219 Fc gamma receptor 504 Fc receptors 504, 828, 846, 868, 1350, 2230 Fc-IgG receptors CD16 and CD32 538 fear 520 febuxostat 149, 154, 158 feet involvement 1759 fellowship training 45, 47 ferritin 102, 916, 923 fertility 1043, 1145 fetal loss 1193, 1860 fever 897, 2105 fewer male siblings 1193 FGF23 1155, 2202 fibrin network 7 fibrinogen 350, 1306 fibroblast 1511 362 2010 Program Book
fibroblast like synoviocyte 27 fibroblast-epithelial cell interactions 613 fibroblast-like synoviocytes 366, 1388 fibroblasts 17, 21, 23, 36, 39, 244, 349, 357, 364, 489, 600, 606, 611, 613, 615, 616, 629, 670, 679, 1089, 1131, 1210, 1274, 1389, 1420, 1506, 1518, 1529, 1722, 1733, 1991, 1999, 2003, 2007, 2231 fibromyalgia 92, 93, 94, 95, 96, 97, 98, 99, 100, 101, 102, 103, 104, 105, 107, 108, 109, 110, 111, 112, 113, 115, 116, 117, 532, 646, 647, 648, 650, 651, 797, 798, 799, 800, 801, 802, 803, 804, 805, 806, 807, 808, 809, 810, 811, 812, 813, 814, 815, 816, 817, 818, 819, 820, 821, 990, 1320, 1681, 2074, 2075, 2109, 2246 fibromyalgia impact questionnaire 115 fibrosing 1212 fibrosis 601, 609, 614, 675, 1210, 2007, 2231 fine-specificity 2114 first-degree relative 77 flare 452, 757, 764, 1362, 1752, 1766, 1778 flare criteria 1688 flip 854 flow cytometry 1492, 1728 Flt3-ligand 293 fluoroquinolone 2212 fMRI 2097 FMS-like tyrosine kinase3-ligand 1914 foam cell 1072 focus group 2281 focus score 1907 follicular dendritic cells 730 follow-up 1963 foot 173 foot disorders 1327, 1328, 1329, 1330, 1331 foot pain 1327 formal joint count 995 Fourier-transform infrared spectroscopy 875 Foxp3 909, 1257 Foxp3+ Treg cells 1266, 1499 fracture risk 1552 fractures 31, 960, 963, 966, 968, 969, 971, 976, 977, 979, 980, 982, 989, 999, 1005, 1546, 2089, 2112, 2157 frailty 186 FRAX 968, 1156 free fatty acids 1034 free heavy chain 1450 function 806, 814 functional connectivity 650 functional impairment 115 functional MRI 1159 functional status 186, 189, 314, 555, 1749, 1755, 2069, 2076, 2095, 2138, 2142 fungal infection 415 future expectations 2281 G gadolinium contrast agents 1993 gait 200, 201, 202, 2099 gait parameters 2059 gait velocity 2095 galectin 372 gallic acid 27 gastric antral vascular ectasia 726 gastrointestinal complications 298, 535, 726, 945, 946, 953, 1902 Gaucher disease 1653 GAVE 726 gender 440, 1188, 1257, 1557, 2096 gender differences 550 gene compy number 498 gene expression 1188, 1251, 1257, 1578, 1990, 2149 gene expression pr<strong>of</strong>iles 285 gene polymorphism 356, 504 gene regulation 507, 1578 gene therapy 1129, 1413, 1729, 1733, 2174, 2178 gene-environment interactions 1588 generalizability theory 1316 generalized osteoarthritis 182 genetic ancestry 1592 genetic association 831, 838, 841, 1313, 1446, 1979, 2274 genetic association study 1585, 1586 genetic disorders 500, 837, 877, 897, 1329, 1583, 1597, 1599, 1656, 1987, 2105, 2226 genetic epidemiology 828, 1984 genetic factors 1076 genetic markers 1600, 2215 genetic susceptibility 832 genetic variants 1077 genetics 250, 262, 822, 1078, 1355, 1593, 1594, 2146, 2148 GENISOS 1211 genome-wide 836 genome-wide association study 1600, 2219 genomics 2, 242, 243, 247, 250, 251, 254, 255, 258, 264, 266, 495, 496, 498, 502, 573, 653, 654, 655, 823, 825, 826, 829, 830, 842, 843, 928, 1075, 1084, 1099, 1280, 1301, 1386, 1577, 1578, 1579, 1587, 1589, 1590, 1591, 1596, 1597, 1598, 1600, 1603, 1608, 1609, 1610, 1611, 1918, 1969, 1994, 2144, 2146, 2149, 2214, 2215, 2219 genotype-phenotype relationships 843 genotyping 1885 geriatrics 154, 624, 1459, 2045 germinal center 432, 1412 giant cell arteritis 126, 774, 1277, 1280, 1292, 1294, 1296, 1299, 1301, 1304, 1309, 1310, 1311, 1314, 2198, 2199 gingivalis 1717 global 1151 global disease flare 1688 global health 1336 glomerulonephritis 2048 glucocorticoid induced osteoporosis (GIOP) 978, 2156 glucocorticoids 283, 342, 392, 423, 957, 965, 966, 978, 981, 983, 994, 1036, 1123, 1179, 1314, 1397, 1437, 1873, 2159, 2213 GLUT9 164 glutathione 1185 glycosylation 494 golimumab 326, 386, 890, 908, 1097, 1114, 1127, 1136, 1804, 1814, 1815, 1835, 1943, 2264 gout 144, 145, 146, 147, 148, 150, 151, 152, 154, 155, 156, 157, 158, 159, 160, 162, 163, 164, 165, 166, 869, 870, 873, 876, 877, 879, 880, 881, 882, 883, 884, 888, 889, 1362, 1364, 1366, 1423, 1544, 1547, 1556, 1565, 1569, 1572, 1574, 1616, 2087, 2150, 2152, 2153, 2154 growth 1684, 1696 growth factors 259, 2202 GRP78 1729 guideline 2051 GWAS follow-up 1599 gynecologic issues 104, 468 H1N1 224, 450, 1437 H1N1 influenza 235 H1N1 influenza A/California/7/2009 481 hallux valgus 1328 hand 142 hand disorders 187, 708, 940, 1220, 1237, 1749, 2076, 2142 hand dysfunction 2076 hand osteoarthritis 179, 185 haplotype 707, 1280 HAQ 1734 HBV 329 HDAC 750 HDAC2 2029 HDL composition 332 healed arteritis 1311 health assessment questionnaire 166, 314, 690, 779, 1204, 1423, 1425, 1460, 1549, 1755, 1765 health behaviors 87, 156, 776, 1318, 1332, 1428, 1553, 1562, 1576, 1856, 2096 health care 1337 health care disparities 790 health care services 2284 health care utilization 790 health communications 1465 health disparities 1336, 1875 H abstract KEYWORD INDEX 2010 Program Book 363
- Page 1 and 2:
program B O O K Pre-Conference Cour
- Page 3 and 4:
program B O O K ABOUT ACR/ARHP EDUC
- Page 5 and 6:
TABLE OF CONTENTS ACCREDITATION . .
- Page 7 and 8:
TABLE OF CONTENTS ACR/ARHP Poster S
- Page 9 and 10:
TABLE OF CONTENTS Systemic Sclerosi
- Page 11 and 12:
the written consent of the ACR is p
- Page 13 and 14:
Shuttle Bus Service See shuttle sig
- Page 15 and 16:
ACR Resource Center Hours: Sunday,
- Page 17 and 18:
ACR Hotels + Map Complimentary shut
- Page 19 and 20:
to the premier meeting in rheumatol
- Page 21 and 22:
ACR Clinical Research Conference c/
- Page 23 and 24:
4:20 PM Germinal Center Reactions A
- Page 25 and 26:
3:30 PM Live Demonstration: Ultraso
- Page 27 and 28:
Upon completion of this session, pa
- Page 29 and 30:
MONDAY, NOVEMBER 8, 2010 ACR/ARHP R
- Page 31 and 32:
B301 Dermatological Manifestations
- Page 33 and 34:
Session Overview: The innate immune
- Page 35 and 36:
Upon completion of this session, pa
- Page 37 and 38:
B308 Inflammatory Eye Disease P/C M
- Page 39 and 40:
and insufficiency • recall source
- Page 41 and 42:
Session Overview: The advent of bio
- Page 43 and 44:
2:45 pm 641. Major Improvements in
- Page 45 and 46:
5 University of Twente and Medisch
- Page 47 and 48:
ACR/ARHP Combined Abstract Session
- Page 49 and 50:
REF 25th Anniversary Celebration 2:
- Page 51 and 52:
5:45 PM 699. Defining Latent and/or
- Page 53 and 54:
Lilian H. D. van Tuyl 8 , Karin Bri
- Page 55 and 56:
ACR REF Special Sessions 4:30 - 6:0
- Page 57 and 58:
REF 5K Run/Walk 6:00 - 8:00 am See
- Page 59 and 60:
• discuss the principles of early
- Page 61 and 62:
ACR Medical Aspects of Rheumatic Di
- Page 63 and 64:
10:00 am 1349. Work as a Daily Chal
- Page 65 and 66:
ACR Plenary Session II: Discovery 2
- Page 67 and 68:
B210 B301 Pediatrics: Periodic Feve
- Page 69 and 70:
Session Overview: As a clinical edu
- Page 71 and 72:
Thomas J. Murphy Ballroom Giant Cel
- Page 73 and 74:
3:45 PM 1367. Serum Urate Levels in
- Page 75 and 76:
A411 Rheumatoid Arthritis - Human E
- Page 77 and 78:
2:45 PM 1405. Development of a Visi
- Page 79 and 80:
4:30 PM Anti-citrullinated Protein
- Page 81 and 82:
of Experimental Orthopedics, Univer
- Page 83 and 84:
5:30 PM 1438. Mortality/Morbidity i
- Page 85 and 86:
5:30 PM 1456. Belimumab, a BLyS-Spe
- Page 87 and 88:
Develly 5 , Bernardo L. F. Fernande
- Page 89 and 90:
7:30 PM Role of IL-1 in Human Artic
- Page 91 and 92:
• compare the prevalence and epid
- Page 93 and 94:
6:45 PM Macrophage Activation Syndr
- Page 95 and 96:
Upon completion of this session, pa
- Page 97 and 98:
Session Overview: This roundtable d
- Page 99 and 100:
B303 Scleroderma: Systemic Sclerosi
- Page 101 and 102:
9:00 - 10:30 am - Poster Hall Morni
- Page 103 and 104:
• describe the role of IL-1 and I
- Page 105 and 106:
Session Overview: For the clinician
- Page 107 and 108:
• identify the aspects for day-to
- Page 109 and 110:
ACR Study Groups 1:00 - 2:00 PM B30
- Page 111 and 112:
Session Overview: Ultrasound and ma
- Page 113 and 114:
Session Overview: Fifty percent of
- Page 115 and 116:
1:20 PM Academic Rheumatology Seth
- Page 117 and 118:
ACR Concurrent Abstract Sessions 2:
- Page 119 and 120:
3:00 PM 2110. Rheumatologists on th
- Page 121 and 122:
2:45 PM 2133. Reasons for Decline i
- Page 123 and 124:
Session Overview: We are witnessing
- Page 125 and 126:
Session Overview: Systemic sclerosi
- Page 127 and 128:
Oaks, CA, 2 Amgen Inc., San Francis
- Page 129 and 130:
5:00 PM 2176. A Role of Autoimmune
- Page 131 and 132:
4:30 PM 2198. Association between V
- Page 133 and 134:
ARHP Concurrent Sessions 4:30 - 6:0
- Page 135 and 136:
THURSDAY, NOVEMBER 11, 2010 ACR/ARH
- Page 137 and 138:
• apply these basic statistics to
- Page 139 and 140:
9:15 AM The ACR/EULAR Definition of
- Page 141 and 142:
Immunology, Oslo University Hospita
- Page 143 and 144:
9:15 AM 2239. Factors Associated wi
- Page 145 and 146:
Upon completion of this session, pa
- Page 147 and 148:
Mikkel Østergaard 6 , Paul Emery 4
- Page 149 and 150:
Ende 4 , 1 Department of Rheumatolo
- Page 151 and 152:
ACR Poster Session A Cytokines, Med
- Page 153 and 154:
ACR Poster Session A 51. Associatio
- Page 155 and 156:
ACR Poster Session A 83. Respirator
- Page 157 and 158:
ACR Poster Session A 121. Bone Dens
- Page 159 and 160:
ACR Poster Session A 142. The Intra
- Page 161 and 162:
ACR Poster Session A 171. Early Pro
- Page 163 and 164:
ACR Poster Session A Pediatric Rheu
- Page 165 and 166:
ACR Poster Session A 233. Prevalenc
- Page 167 and 168:
ACR Poster Session A 266. Subtype S
- Page 169 and 170:
ACR Poster Session A 297. Body Weig
- Page 171 and 172:
ACR Poster Session A 325. Patient R
- Page 173 and 174:
ACR Poster Session A 356. Influence
- Page 175 and 176:
ACR Poster Session A 383. Efficacy
- Page 177 and 178:
ACR Poster Session A 409. Rituximab
- Page 179 and 180:
ACR Poster Session A 441. Recombina
- Page 181 and 182:
ACR Poster Session A 465. Immunoglo
- Page 183 and 184:
ACR Poster Session A 496. IRF8 Alle
- Page 185 and 186:
ACR Poster Session A 521. DC-STAMP
- Page 187 and 188:
ACR Poster Session A 546. Prevalenc
- Page 189 and 190:
ACR Poster Session A 571. Epidemiol
- Page 191 and 192:
ACR Poster Session A 599. Validatio
- Page 193 and 194:
ACR/ARHP Poster Session B Halls B1
- Page 195 and 196:
ACR Poster Session B 767. Economic
- Page 197 and 198:
ACR/ARHP Poster Session B 792. The
- Page 199 and 200:
ACR/ARHP Poster Session B Universit
- Page 201 and 202:
ACR/ARHP Poster Session B 848. Cell
- Page 203 and 204:
ACR/ARHP Poster Session B 886. Scre
- Page 205 and 206:
ACR/ARHP Poster Session B 909. Regu
- Page 207 and 208:
ACR/ARHP Poster Session B 935. The
- Page 209 and 210:
ACR/ARHP Poster Session B 967. Frac
- Page 211 and 212:
ACR Poster Session B 993. Early Exp
- Page 213 and 214:
ACR/ARHP Poster Session B 1022. Com
- Page 215 and 216:
ACR/ARHP Poster Session B 1055. Son
- Page 217 and 218:
ACR Poster Session B 1084. Gene Exp
- Page 219 and 220:
ACR/ARHP Poster Session B 1111. Inc
- Page 221 and 222:
ACR Poster Session B hiroshima Memo
- Page 223 and 224:
ACR/ARHP Poster Session B 1166. Pre
- Page 225 and 226:
ACR/ARHP Poster Session B 1199. Typ
- Page 227 and 228:
ACR/ARHP Poster Session B 1225. Phy
- Page 229 and 230:
ACR/ARHP Poster Session B 1262. Lat
- Page 231 and 232:
ACR/ARHP Poster Session B 1294. End
- Page 233 and 234:
ACR/ARHP Poster Session B 1321. Cha
- Page 235 and 236:
ACR/ARHP Poster Session C Halls B1
- Page 237 and 238:
ACR/ARHP Poster Session C 1495. S10
- Page 239 and 240:
ACR/ARHP Poster Session C 1524. Inc
- Page 241 and 242:
ACR/ARHP Poster Session C 1555. Pro
- Page 243 and 244:
ACR/ARHP Poster Session C 1583. Ass
- Page 245 and 246:
ACR/ARHP Poster Session C 1596. Gen
- Page 247 and 248:
ACR/ARHP Poster Session C 1622. Flu
- Page 249 and 250:
ACR/ARHP Poster Session C Miscellan
- Page 251 and 252:
ACR/ARHP Poster Session C L. Woodwa
- Page 253 and 254:
ACR/ARHP Poster Session C 1692. Res
- Page 255 and 256:
ACR/ARHP Poster Session C 1719. Los
- Page 257 and 258:
ACR/ARHP Poster Session C 1749. Con
- Page 259 and 260:
ACR/ARHP Poster Session C 1780. Tow
- Page 261 and 262:
ACR/ARHP Poster Session C 1804. Eff
- Page 263 and 264:
ACR/ARHP Poster Session C Immunolog
- Page 265 and 266:
ACR/ARHP Poster Session C 2 Departm
- Page 267 and 268:
ACR/ARHP Poster Session C CA, 29 Un
- Page 269 and 270:
ACR/ARHP Poster Session C 1900. IL-
- Page 271 and 272:
ACR/ARHP Poster Session C 1930. Cor
- Page 273 and 274:
ACR/ARHP Poster Session C 1958. The
- Page 275 and 276:
ACR/ARHP Poster Session C 1988. Cha
- Page 277 and 278:
ACR/ARHP Poster Session C 2015. CpG
- Page 279 and 280:
ACR/ARHP Poster Session C 2038. Pri
- Page 281 and 282:
ACR/ARHP Poster Session C 2070. Ass
- Page 283 and 284:
REF Industry Roundtable-supported S
- Page 285 and 286:
REF Industry Roundtable-supported S
- Page 287 and 288:
INDUSTRY-SUPPORTED POST-CONFERENCE
- Page 289 and 290:
2010 ACR/ARHP Annual Meeting Leader
- Page 291 and 292:
2010 ACR/ARHP Annual Meeting Leader
- Page 293 and 294:
FLOOR PLANS 2010 Program Book 291
- Page 295 and 296:
VISIT THE EXHIBIT HALL New and inno
- Page 297 and 298:
EXHIBITORS La Lettre Du Rhumatologu
- Page 299 and 300:
ACKNOWLEDGEMENTS The ACR, the ARHP
- Page 301 and 302:
ACR/ARHP/REF STAFF LISTING Administ
- Page 303 and 304:
A Ahmed, Rafi, PhD T cell Memory .
- Page 305 and 306:
Cooper, Max D, MD Introduction . .
- Page 307 and 308:
Gerlag, Danielle Marie, MD, PhD The
- Page 309 and 310:
Physical Examination Skills for Imp
- Page 311 and 312:
Meroni, Pierluigi, MD Autoantibodie
- Page 313 and 314: Rogers, Joan C, PhD, OTR/ L Underst
- Page 315 and 316: Terkeltaub, Robert, MD Crystallizin
- Page 317 and 318: A Aarden, L 1825 Aarrass, S 1519, 1
- Page 319 and 320: Bakker, AAB 1095 Barendregt, B 753
- Page 321 and 322: Boutin-Le Thi Huong, D 478 Bout-Tab
- Page 323 and 324: Chatham, WW 457, 1146, 1454, 1457,
- Page 325 and 326: Daudon, M 875 Daugas, E 2009 Davatc
- Page 327 and 328: Ehst, B 758 Eicher, JL 688 Eisen, S
- Page 329 and 330: Gabay, OH 1484 Gaber, T 630, 1418 G
- Page 331 and 332: Guan, M 965 Guañabens, N 975 Gudbj
- Page 333 and 334: Homme, CL 730 Honda, E 434 Hong, JY
- Page 335 and 336: Kambayashi, T 1354 Kamdar, AA 1160
- Page 337 and 338: Kuller, LH 71 Kumabe, M 1164 Kumaga
- Page 339 and 340: Looney, C 941 Looney, MR 609 Looney
- Page 341 and 342: McCarthy, GM 1109, 1306, 1426 McCau
- Page 343 and 344: Myouzen, K 1577 Mysiw, WJ 2096 Mysl
- Page 345 and 346: Pans, M 1834 Parra, ER 605, 887 Ped
- Page 347 and 348: Radka, S 1174 Radner, H 296, 1745 R
- Page 349 and 350: Sack, KE 1898 Sacli, SF 1312 Saddic
- Page 351 and 352: 1463, 2071, 2140, 2141 Singh, K 212
- Page 353 and 354: Takahata, M 1492 Takasaki, Y 1731 T
- Page 355 and 356: 636 van Dongen, CJJ 90 Van Doornum,
- Page 357 and 358: Witte, T 824, 1578, 1579, 2214 Witt
- Page 359 and 360: A α-galactosylceramide 505 A2A kno
- Page 361 and 362: Behcet’s syndrome 1284, 1288, 129
- Page 363: cost-utility 759, 1539 couples 1324
- Page 367 and 368: impact 1063, 1325 inactive disease
- Page 369 and 370: methylation 826, 1253, 1489 methylt
- Page 371 and 372: 233, 234, 240, 243, 252, 262, 268,
- Page 373 and 374: 1599, 1600, 1603, 1605, 1606, 1609,
- Page 375 and 376: 1226, 1227, 1229, 1230, 1231, 1233,
- Page 377 and 378: Abelson, Abby Goulder, MD Education
- Page 379 and 380: Massarotti, Elena M, MD Systemic Lu
- Page 381 and 382: ACR Annual Meeting fellowS-in-train
- Page 383 and 384: NOTES 2010 Program Book 381
- Page 385 and 386: Enbrel ® (etanercept) Brief Summar
- Page 387 and 388: Prescription Enbrel ® (etanercept)